Home/Filings/4/0001439222-21-000056
4//SEC Filing

Bowden Christopher 4

Accession 0001439222-21-000056

CIK 0001439222other

Filed

Jun 8, 8:00 PM ET

Accepted

Jun 9, 4:06 PM ET

Size

14.3 KB

Accession

0001439222-21-000056

Insider Transaction Report

Form 4
Period: 2021-06-07
Bowden Christopher
Chief Medical Officer
Transactions
  • Sale

    Common stock

    2021-06-07$60.04/sh4,268$256,23215,487 total
  • Exercise/Conversion

    Common stock

    2021-06-08$39.76/sh+6,675$265,39822,162 total
  • Exercise/Conversion

    Stock option (right to buy)

    2021-06-086,67532,389 total
    Exercise: $39.76Exp: 2026-02-15Common stock (6,675 underlying)
  • Sale

    Common stock

    2021-06-08$60.07/sh6,675$400,93915,487 total
  • Exercise/Conversion

    Common stock

    2021-06-07$39.76/sh+4,268$169,69619,755 total
  • Exercise/Conversion

    Stock option (right to buy)

    2021-06-074,26839,064 total
    Exercise: $39.76Exp: 2026-02-15Common stock (4,268 underlying)
Footnotes (5)
  • [F1]This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F3]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.10. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F4]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F5]This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Issuer

AGIOS PHARMACEUTICALS, INC.

CIK 0001439222

Entity typeother

Related Parties

1
  • filerCIK 0001608601

Filing Metadata

Form type
4
Filed
Jun 8, 8:00 PM ET
Accepted
Jun 9, 4:06 PM ET
Size
14.3 KB